Richard Burkhart

13PUBLICATIONS
179CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 14, 2026
Clinical, genomic, and spatial transcriptomic features of pancreatic adenosquamous carcinoma support subtype-specific therapeutic strategies.

|May 05, 2026
Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer.

|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Parul Agarwal, Matthew Guo, Kabeer Munjal

|Apr 28, 2025
Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations.

Michelangelo Marasco, Dinesh Kumar, Santiago Garcia Borrego

|Aug 14, 2024
Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC.

Mari Nakazawa, Mike Fang, Tyrus Vong

|Apr 08, 2024
Transfer Learning Reveals Cancer-Associated Fibroblasts Are Associated with Epithelial-Mesenchymal Transition and Inflammation in Cancer Cells in Pancreatic Ductal Adenocarcinoma.

Samantha Guinn, Benedict Kinny-Köster, Joseph A Tandurella

Pageof 3

Frequent Collaborators

6 joint publications

Jin He

6 joint publications

Elizabeth M Jaffee

5 joint publications

Jacquelyn W Zimmerman

4 joint publications

Lei Zheng